The U.S. Food and Druga Administration has approved an injectable drug to treat schizophrenia.
The drug is a long-acting version of aripiprazole (Abilify), and will be available in one-month and six-week formulations, Medical Page Today reports.

The FDA said the drug demonstrated efficacy in a 12-week trial of more than 600 patients. It will contain a boxed warning alerting healthcare professionals that there is an increased risk of death associated with off-label use, the drug agency said in an announcement posted on its website.

"Having a variety of treatment options and dosage forms available for patients with mental illness is important so that a treatment plan can be tailored to meet the patient's needs," said Mitchell Mathis, M.D., the director of psychiatry products at the FDA's Center for Drug Evaluation and Research, in a press release.